How OTC Pain Medications May Fuel Antibiotic Resistance

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTAmanda (Mandy) Mullins, PharmD, BCPSClinical Pharmacist PractitionerVeterans AffairsPRACTICE RESOURCEPurchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcastCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia.2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy.Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose.  0.05 CEU/0.5 HrUAN: 0107-0000-25-371-H01-PInitial release date: 12/15/2025Expiration date: 12/15/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTGeoff Wall, PharmD, FCCP, BCPSProfessor of Pharmacy PracticeIowa Methodist Medical CenterRachel Maynard and Geoff Wall have no relevant financial relationships to disclose.  CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency.2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers.0.05 CEU/0.5 HrUAN: 0107-0000-25-363-H01-PInitial release date: 12/1/2025Expiration date: 12/1/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTHunter Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship CoordinatorSSM HealthJoshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.   CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify newly FDA-approved antibiotics and their clinical indications.2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects.0.05 CEU/0.5 HrUAN: 0107-0000-25-362-H01-PInitial release date: 11/24/2025Expiration date: 11/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Discover the benefits of implementing a long-acting injectable (LAI) service at your pharmacy practice site and the impact this service can have on patient care and outcomes. Listen to this week’s episode and learn how to elevate your pharmacy services! HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTLindsay McCoy, PharmD, BCPPPharmacy ManagerVillage Drug Shop at AdvantageCPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Analyze the benefits and challenges of implementing a long-acting injectable (LAI) service in a pharmacy practice site.2. Discuss how an LAI service can improve patient care, increase financial sustainability, and optimize patient outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-354-H01-PInitial release date: 11/17/2025Expiration date: 11/17/2026Additional CPE details can be found here.Take your pharmacy practice to the next level with our comprehensive course on the administration of long-acting injectables:Pharmacy-Based Administration of Long-Acting Injectables: A Sharp Idea4 hours  |  On DemandExplore a cutting edge clinical service opportunity with this collection of courses specifically designed to equip pharmacists with the knowledge and skills necessary for the effective management and administration of long-acting injectable medications (LAIs). Course content explores diverse drug profiles, advanced administration techniques, and the strategic implementation of LAI-related services to support the needs of your patients and communities.Follow CEimpact on Social Media:LinkedInInstagram

Opioids remain a cornerstone of palliative care for patients with serious illnesses like cancer, yet their use is often misunderstood, undertreated, or approached with unnecessary hesitation. This episode explores what pharmacists need to know about assessing opioid appropriateness, questioning therapy when warranted, and supporting comfort-focused care within established clinical and ethical standards. Tune in to build confidence in your role and contribute meaningfully to the care of patients facing serious illness. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTLorin Fisher, PharmD, BCACPClinical Assistant ProfessorUniversity of Iowa College of PharmacyJoshua Davis Kinsey and Lorin Fisher have no relevant financial relationships to disclose.CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify the role of opioids in managing pain and other symptoms for patients receiving palliative care.2. Describe key considerations for evaluating opioid prescriptions in the context of serious illness, including appropriate use and safety concerns. 0.05 CEU/0.5 HrUAN: 0107-0000-25-330-H01-PInitial release date: 11/10/2025Expiration date: 11/10/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPAProfessorUniversity of Florida College of PharmacyJoshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.0.05 CEU/0.5 HrUAN: 0107-0000-25-312-H01-PInitial release date: 11/3/2025Expiration date: 11/3/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, but recent data suggest a potential link to a higher risk of various ocular disorders, especially with long-term use. This episode reviews the findings of these studies, places them in context with the overall benefits of GLP-1s, and covers what pharmacists should know when counseling patients. Listen in to enhance your ability to guide safe, informed medication choices and stay updated on emerging safety information. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJamie Pitlick, PharmD, BCPS, BC-ADMProfessor and Chair of Pharmacy PracticeDrake University College of Pharmacy and Health SciencesJoshua Davis Kinsey and Jamie Pitlick have no relevant financial relationships with ineligible companies to disclose.  CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the potential relationship between GLP-1 receptor agonist use and the development of ocular disorders.2. Identify key considerations for pharmacist counseling related to GLP-1 therapy and ocular health.0.05 CEU/0.5 HrUAN: 0107-0000-25-311-H01-PInitial release date: 10/27/2025Expiration date: 10/27/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Diagnosis and prescribing are no longer on the margins for pharmacy practice, but explicitly called out in the ACPE Standards that guide pharmacy education. Once considered out of bounds for pharmacists, diagnostic reasoning is now central to preparing practice-ready graduates. This episode explores how preceptors can support learners in applying clinical decision-making frameworks, integrating shared decision-making, and navigating prescriptive authority across diverse practice settings—equipping the next generation of pharmacists for expanded patient care.HOSTKathy Schott, PhDVice President, Education & OperationsCEimpactGUESTSJennifer Adams, PharmD, EdDAssociate Professor, Associate Dean for Academic AffairsIdaho State University L.S. Skaggs College of PharmacyRachel AllenAssociate Teaching ProfessorUniversity of Washington School of PharmacyCherith Smith, PharmDClinical Assistant Professor and Director, Experiential EducationUniversity of Montana – College of Health Skaggs School of PharmacyKathy Schott, Jennifer Adams, Rachel Allen, and Cherith Smith have no relevant financial relationships with ineligible companies to disclose. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesAt the end of this course, preceptors will be able to:1. Describe key principles of diagnostic reasoning and prescribing within the context of pharmacy practice.2. Identify evidence-based frameworks such as the One-Minute Preceptor and shared decision-making to support learner development in clinical settings.0.05 CEU/0.5 HrUAN: 0107-0000-25-319-H99-PInitial release date: 10/15/2025Expiration date: 10/15/2028Additional CPE details can be found here.This program has been:Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.Follow CEimpact on Social Media:LinkedInInstagram